510(k) device
NeuraGen 3D Nerve Guide Matrix
Integra LifeSciences Corporation · Cuff, Nerve (JXI, Class II) · First FDA decision Apr 24, 2014, newest Jan 6, 2017Peripheral neuropathy and nerve injury
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
2
Naming "NeuraGen 3D"
MAUDE reports
1
Brand "NeuraGen 3D", since 2015
PubMed studies
0
Mentioning "NeuraGen 3D"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing NeuraGen 3D Nerve Guide Matrix
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K163457 · Decided Jan 6, 2017 · 28 days after receipt
Device type: Cuff, Nerve (JXI) · Neurology & Neurosurgery
- NEURAGEN 3D510(k)
K130557 · Decided Apr 24, 2014 · 416 days after receipt
Device type: Cuff, Nerve (JXI) · Neurology & Neurosurgery
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Vagus Nerve Stimulation (VNS)National determinationOn the books160.18Updated Nov 5, 2026
- Vagus Nerve Stimulation for Treatment of Resistant Depression (TRD)National analysisReview closedCAG-00313RUpdated Sep 24, 2026
- Vagus Nerve Stimulation (VNS) for Treatment Resistant Depression (TRD)National analysisReview closedCAG-00313R2Updated Sep 24, 2026
- Transcutaneous Electrical Nerve Stimulation for Chronic Low Back PainNational analysisReview closedCAG-00429NUpdated Sep 24, 2026
- Cavernous Nerves Electrical Stimulation with Penile PlethysmographyNational analysisReview closedCAG-00311NUpdated Sep 17, 2026
- Sacral Nerve Stimulation for Urge Urinary IncontinenceNational analysisReview closedCAG-00058NUpdated Sep 15, 2026
- Electrodiagnostic Sensory Nerve Conduction ThresholdNational analysisReview closedCAG-00106RUpdated Sep 14, 2026
- Electrodiagnostic Sensory Nerve Conduction ThresholdNational analysisReview closedCAG-00106NUpdated Sep 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "NeuraGen 3D", any status and sponsor, newest update first.
Integra LifeSciences CorporationPublic (IART)
NCT05339594 · 17 participants · Start May 30, 2022 · Primary completion Jun 3, 2024
Device: NeuraGen; NeuraGen 3D · For: Peripheral Nerve Injuries
Sites: Indianapolis, Indiana; St Louis, Missouri; The Bronx, New York · 6 sites in all
- NeuraGen 3D Pilot StudyTerminated
Integra LifeSciences CorporationPublic (IART)
NCT05343143 · 1 participants · Start May 15, 2022 · Primary completion Jul 11, 2023
Device: NeuraGen 3D Nerve Guide Matrix · For: Digital Nerve Injury
Sites: New York, New York; Durham, North Carolina; Columbus, Ohio · 4 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "NeuraGen 3D", and for the whole product code for context.
This brand
1 reports: 1 malfunction, 0 injury, 0 death
Whole product code JXI
127 reports: 19 malfunction, 106 injury, 0 death
Newest reports for this brand
- NEURAGEN 3D NERVE GUIDE MATRIX 7MM X 3CMMalfunction
INTEGRA LIFESCIENCES CORPORATION
1121308-2022-00086 · Received Jul 25, 2022 · Event dated Jun 27, 2022
Device type: Block, Bite (JXL)
Device problem as coded: Material Integrity Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "NeuraGen 3D"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code JXI.
- VersaWrap Nerve Protector (VTP-2201)Alafair Biosciences · 510(k) 2025
- Neurolac(R) Nerve GuidePolyganics B.V. · 510(k) 2011
- Axoguard HA+ Nerve Protector (AGHA12)Axogen Corporation · 510(k) 2023
- Reaxon PlusMedovent GmbH · 510(k) 2018
- Collagen Nerve WrapCollagen Matrix, Inc. · 510(k) 2006
- SILKBridgeKLISBio S.r.l. · 510(k) 2026
- NeuroSpan BridgeAuxilium Biotechnologies, Inc. · 510(k) 2026
- VersaCoat Nerve Protector (VTP-44G2)Alafair Biosciences · 510(k) 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.